According to the research report, the global formulation development outsourcing market size is expected to touch USD 75.8 Billion by 2032, from USD 37.4 Billion in 2022, growing with a significant CAGR of 7.32% from 2023 to 2032.
Key Takeaways:
- By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
- By service, the formulation development generated over 77% of revenue share in 2022.
- By formulation, the oral segment had the largest market share of 64% in 2022.
- By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
- By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.
The formulation development outsourcing report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global formulation development outsourcing in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global formulation development outsourcing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global formulation development outsourcing during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3192
This study covers a detailed segmentation of the global formulation development outsourcing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global formulation development outsourcing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- SGS S.A.
- Eurofins Scientific SE
- Element
- Labcorp
- Thermo Fisher Scientific, Inc. (Patheon)
- Intertek Group plc
- Recipharm
- Lonza
- Charles River Laboratories International, Inc.
- Catalent Inc.
Market Segmentation
By Service
- Preformulation
- Formulation Development
By Formulation
- Topical
- Oral
- Injectable
- Others
By Therapeutic Area
- Oncology
- Infectious Disease
- Respiratory
- Cardiovascular
- Neurology
- Hematology
- Dermatology
- Others
By End-User
- Pharmaceutical Industries
- Research and Academic Institutions
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global formulation development outsourcing report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global formulation development outsourcing market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market
5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Formulation Development Outsourcing Market, By Service
8.1. Formulation Development Outsourcing Market, by Service, 2023-2032
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Formulation Development Outsourcing Market, By Formulation
9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area
10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Infectious Disease
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Respiratory
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cardiovascular
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Neurology
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Hematology
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Dermatology
10.1.7.1. Market Revenue and Forecast (2020-2032)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Formulation Development Outsourcing Market, By End-User
11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032
11.1.1. Pharmaceutical Industries
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Research and Academic Institutions
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 13. Company Profiles
13.1. SGS S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Element
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Labcorp
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific, Inc. (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Recipharm
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lonza
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories International, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Catalent Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments